Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • Revolution Medicines' Capital Expenditures fell 4.86% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 34.06%. This contributed to the annual value of $10.3 million for FY2024, which is 33.37% up from last year.
  • Revolution Medicines' Capital Expenditures amounted to $3.3 million in Q3 2025, which was down 55.05% from $7.5 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Capital Expenditures high stood at $7.5 million for Q2 2025, and its period low was $454,000 during Q3 2021.
  • Moreover, its 3-year median value for Capital Expenditures was $2.5 million (2023), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Revolution Medicines' Capital Expenditures skyrocketed by 676.43% in 2022, and later slumped by 55.70% in 2023.
  • Over the past 5 years, Revolution Medicines' Capital Expenditures (Quarterly) stood at $1.2 million in 2021, then spiked by 143.11% to $2.9 million in 2022, then fell by 19.44% to $2.3 million in 2023, then crashed by 47.26% to $1.2 million in 2024, then decreased by 4.86% to $3.3 million in 2025.
  • Its Capital Expenditures stands at $3.3 million for Q3 2025, versus $7.5 million for Q2 2025 and $3.3 million for Q1 2025.